Medicamentos na Prática Clinica - Barros - 1ed-126

Prévia do material em texto

126 Elvino Barros, Helena M. T. Barros & Cols. 
TABELA9.7 
Níveis e parâmetros farmacocinéticos dos medicamentos antirretrovirais - inibidores da protease (IP) 
e inibidores não nucleosídeos da transcriptase reversa (INNTR) 
Medicamento Níveis terapêuticos Níveis tóxicos Meia-vida 
Atazanavir (IP) 150-850 ng/ml * 3, 1-9, 1 h 
lndinavir (IP) 100-500 ng/ml 1.000 ng/ml 1,05-2 h 
Nelfinavir (IP) 800-600 ng/ml * 3,5-5 h 
Saquinavir (IP) 250-600 ng/ml * 7-12 h 
Ritonavir (IP) 1.500-2.100 ng/ml ** * 3-5 h 
Nevirapina (INNTR) 3.400 ng/ml * * 25-30 h (inicial: 45 h) 
Efavirenz (INNTR) 1.000 ng/ml * 4.000 ng/ml 52-76 h 
*Dados não encontrados na literatura. 
**O ritonavir é usado como adjuvante. Essa faixa de concentração considera seu uso isoladamente. 
REFERÊNCIAS 
Armstrong VW, Streit E Drug monitoring of Sirolimus and Everolimus. Lab Med. 2003; 2 7 (5/6) :222-
27. 
Baselt RC. Biological monitoring methods for industrial chemicals. California: Biomedical Publi-
cations Davis; 1994. 
Bezchlibnyk-Butler KZ, Jeffries JJ, Virani AS. Clinicai handbook of psychotropic drugs. 17th ed. 
Ohio: Hogrefe; 2007. 
Bommi EMGV, Raghoebar M, Tukker JJ. Kinetics of acetaminophen after single- and multiple-dose 
oral administration as a gradient matrix system to healthy male subjects. Biopharma Drug Dispos. 
2006; 12 (5) :355-66. 
Bruton LL, Lazo JSL, Parker KL. Goodman & Gilman's. llth ed. New York: McGraw-Hill; 2005. 
De Leon J, Diaz FJ, Wedlund P, Josiassen RC, Cooper TB, Simpson GM. Haloperidol half-life after 
chronic dosing. J Clin Psychopharmacol. 2004;24(6):656-60. 
Flomenbaum NE, Howland MA, Goldfrank LR, Lewin NA, Hoffman RS, Nelson LS. Goldfrank's 
toxicologic emergencies. 8th ed. New York: McGraw-Hill; 2002. 
Ford MO, Delaney KA, Ling LJ, Erickson T. Clinicai toxicology. Philadelphia: Saunders Company; 
2001. 
França GV. Medicina legal. 5. ed. Rio de Janeiro: Guanabara koogan; 1998. 
Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is mo-
nitoring needed? Clin Pharmacokinet. 2006;45(11):1061-75. 
Korolkovas A, França FFAC. Dicionário Terapêutico Guanabara. 12. ed. Rio de Janeiro: Guanaba-
ra-Koogan; 2005. 
Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook. 15th ed. Ohio: Lexi-
Comp.; 2007. 
Leiking JB, Paloucek FP. Poisoning & toxicology compendiun. Ohio: Lexi-comp.; 1998. 
Luina MY, Kuksb PFM, Burgera M. Use of therapeutic drug monitoring in HIV disease. Curr Opin 
HIV and AIO. 2008;3(3) :266-71. 
Morse GD, Catanzaro LM, Acosta EP. Clinicai pharmacodynamics of HIV-1 protease inhibitors: use 
of inhibitory quotients to optimise pharmacotherapy. Lancet Infect Ois. 2006;6(4):215-25. 
Õnal A. Analysis of antiretroviral drugs in biological matrices for therapeutic drug monitoring. J 
Food Drug Analys. 2006;14(2):99-119.